Viking Therapeutics Inc.

Last updated September 27, 2026

Organization details

Legal name
Viking Therapeutics Inc.
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
SAN Diego
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
VKTX
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001607678
EIN
46-1073877

Board of directors

Chief executives

Brian Lian · President & CEO
Dates unknown

Director election results

Annual meeting of May 19, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

1 of this board's directors also sit on 1 other board. 1 is in the same sector.

Network of Viking Therapeutics Inc.'s board connections OmniAb Inc. OmniAb Inc. Matthew W. Foehr Matthew W. Foehr Viking Therapeutics Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$149,913
1 purchase by 1 insider
Sold, last 12 months
$18,320,912
16 sales by 4 insiders
Date Insider Transaction Shares Price Value
Aug 1, 2026 Dorothy Elizabeth Kelly-Gemmell Director Grant or award +6,333 — —
Jul 29, 2026 Brian Lian Director, Officer (President & CEO) Open-market sale −148,517 $33.32 $4,948,586
Jul 29, 2026 Mancini Marianna Officer (Chief Operating Officer) Open-market sale −18,217 $33.47 $609,723
Jul 29, 2026 ZANTE GREG Officer (Chief Financial Officer) Open-market sale −21,217 $33.47 $710,133
Jul 28, 2026 Brian Lian Director, Officer (President & CEO) Grant or award +221,667 — —
Jul 28, 2026 Mancini Marianna Officer (Chief Operating Officer) Grant or award +31,667 — —
Jul 28, 2026 ZANTE GREG Officer (Chief Financial Officer) Grant or award +31,667 — —
Mar 10, 2026 Aubuchon Neil William Officer (Chief Commercial Officer) Open-market purchase +4,475 $33.50 $149,913
Jan 5, 2026 ZANTE GREG Officer (Chief Financial Officer) Open-market sale −31,961 $32.30 $1,032,340
Jan 5, 2026 Mancini Marianna Officer (Chief Operating Officer) Open-market sale −31,961 $32.29 $1,032,021
Jan 5, 2026 Brian Lian Director, Officer (President & CEO) Open-market sale −132,454 $32.29 $4,276,940
Jan 5, 2026 ZANTE GREG Officer (Chief Financial Officer) Open-market sale −13,900 $33.38 $463,982
Jan 5, 2026 Mancini Marianna Officer (Chief Operating Officer) Open-market sale −13,600 $33.37 $453,832
Jan 5, 2026 Brian Lian Director, Officer (President & CEO) Open-market sale −53,279 $33.38 $1,778,453
Jan 5, 2026 ZANTE GREG Officer (Chief Financial Officer) Open-market sale −10,300 $34.24 $352,672

Organizations in the same sector, closest in location and size first.

Questions about Viking Therapeutics Inc.

Who is the CEO of Viking Therapeutics Inc.?

Brian Lian is Viking Therapeutics Inc.'s President & CEO.

How many directors are on Viking Therapeutics Inc.'s board?

Viking Therapeutics Inc.'s board has 7 directors: Brian Lian, Charles A. Rowland Jr., Dorothy Elizabeth Kelly-Gemmell, J. Matthew Singleton, Lawson Macartney, Matthew W. Foehr and Sarah Kathryn Rouan.

Are Viking Therapeutics Inc. insiders buying or selling shares?

Over the last 12 months, Viking Therapeutics Inc. insiders bought $149,913 of shares in 1 purchase and sold $18.3 million of shares in 16 sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="viking-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.